Hikma Pharmaceuticals (GB:HIK) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive audit tender process. As part of regulatory requirements, Hikma must rotate auditors every 20 years, and this decision awaits shareholder approval at the 2026 Annual General Meeting. Investors may find this continuity in auditing services a point of stability for the company’s financial oversight.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.
